Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MTOR | P42345 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.35 |
| ▸ | ALB | P02768 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.35 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236109 | 0.91 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL6932187 | 0.88 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL6932196 | 0.88 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL5824290 | 0.88 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Phosphoric Acid SCHEMBL21465061 | 0.87 | PDE3A (0.45) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL26109412 | 0.86 | PDE3A (0.44) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL30514303 | 0.84 | LMNA (0.50) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL331769 | 0.83 | LMNA (0.49) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL26666720 | 0.83 | LMNA (0.49) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL10612101 | 0.81 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | claimed |
| EP-0831849-A4 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | WELLSTAT THERAPEUTICS CORP (US) | 2003-03-26 | — | — | EP | claimed |
| US-6344447-B2 | ADMINISTERING MIXTURE OF NUCLEOSIDES; ANTICANCER AGENT | PRO-NEURON, INC. | 2002-02-05 | — | — | US | claimed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | claimed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | claimed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | claimed |
| CN-1192149-A | Methods of reducing toxicity of chemotherapeutic and antiviral agents with acylated pyrimidine nucleosides | PRO NEURON INC (US) | 1998-09-02 | — | — | CN | claimed |
| EP-0831849-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1998-04-01 | — | — | EP | claimed |
| JP-2584947-B2 | — | — | 1997-02-26 | — | — | JP | claimed |
| WO-1996040165-A1 | METHODS OF REDUCING TOXICITY OF CHEMOTHERAPEUTIC AND ANTIVIRAL AGENTS WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0594667-A4 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 1996-01-10 | — | — | EP | claimed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | claimed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | claimed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | claimed |
| US-7776838-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2010-08-17 | — | — | US | disclosed |
| US-7166581-B1 | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| EP-1491201-B1 | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | WELLSTAT THERAPEUTICS CORP (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0594667-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| WO-1993001202-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1993-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | PDE3A 2553/4885PDE4D 2101/4885SLC29A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.